The comparison to NEU hasn't been elaborated. Morgans might be comparing the business model of NEU and licencing of their drug to Acadia in the USA to ANP and another pharma. If they are talking about SP, then Sam hit the nail on the head as Morgans 12 month estimate is 0.23c.
The comparison to NEU hasn't been elaborated. Morgans might be...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 7.9¢ | 7.9¢ | 7.6¢ | $26.62K | 343.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 113467 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.7¢ | 98248 | 1 |
View Market Depth
| Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.7¢ |
Change
0.000 ( 1.28 %) |
||||
| Open | High | Low | Volume | ||
| 7.9¢ | 7.9¢ | 7.7¢ | 14800 | ||
| Last updated 15.52pm 06/05/2024 ? | |||||
| PER (ASX) Chart |